We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Third-Party Manufacturer Inspection Nets Checkpoint Therapeutics a CRL
Third-Party Manufacturer Inspection Nets Checkpoint Therapeutics a CRL
Checkpoint Therapeutics announced that the FDA has issued a complete response letter (CRL) for its cosibelimab BLA based on an inspection of the company’s third-party manufacturer, with no issues cited on the approvability of the drug itself.